Innovative therapies to treat and cure
hepatitis B virus (HBV) and other viral diseases

The only Active Site Polymerase Inhibitor Nucleotide (ASPIN) in Development

Combining the ASPIN, ATI-2173, with a Nucleoside Analogue (NA), such as Tenofovir (TDF) or Entecavir (ETV), in a one-pill, once-a-day regimen could completely shut down HBV polymerase activity and viral replication, potentially curing HBV infected individuals